Search clinical trials for: Dapagliflozin 10 mg/day (oral)

Total 3368 results

Damanhour University

Recruiting

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Heart Failure | Reduced Ejection Fraction Heart Failure

Egypt
AstraZeneca

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (BalanceD-HF)

Heart Failure and Impaired Kidney Function

Spain, France, Germany, Italy, United States, Argentina, Czechia, Vietnam, Peru, China, Philippines, Saudi Arabia, Australia, Austria, Canada, Japan, Malaysia, Poland, Taiwan, Thailand, Israel, Brazil, Finland, Greece, Mexico, United Kingdom and more
University Medical Center Groningen
AstraZeneca; Dutch Kidney Foundation

Enrolling by invitation

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

Heart Failure | Death | Kidney Disease, Chronic | Kidney Failure | Renal Transplant Failure

Netherlands, Germany, Australia
Medical University of Warsaw
Medical University of Graz; Medical University of Vienna; Poznan University of... and other collaborators

Recruiting

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY)

Acute Decompensated Heart Failure

Poland
AstraZeneca

Recruiting

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease. (MIRO-CKD)

Chronic Kidney Disease

Spain, Italy, China, Vietnam, United States, Brazil, Canada, Malaysia, Poland, Taiwan, Austria, Bulgaria, Chile, United Kingdom, Japan
Immunic AG

Active, not recruiting

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) (EMPhASIS)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Poland, Bulgaria, Romania, Ukraine
Fundación Pública Andaluza para la Investigación...

Unknown

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

Type 2 Diabetes Mellitus

Spain
University Health Network, Toronto

Recruiting

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients (INFINITI2019)

Type 2 Diabetes | Kidney Transplant Recipients | Post-transplant Diabetes Mellitus

Canada
Brigham and Women's Hospital

Unknown

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

Diabetes Mellitus, Type 2

United States
Ferring Pharmaceuticals

Terminated

Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Sweden, Canada, Hungary, United States, Brazil, South Africa, Czech Republic, Germany, Mexico, Poland, Slovakia, United Kingdom
Ain Shams University

Not yet recruiting

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Lupus Nephritis

Egypt
LM Diagnósticos S.L.
AstraZeneca

Unknown

Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes

Type2 Diabetes

Spain
Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
University of Oxford
Oxford Brookes University; The Leona M. and Harry B. Helmsley Charitable Trust

Terminated

Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia (DEPTH)

Diabetes Mellitus, Type 1

United Kingdom
University Health Network, Toronto
Sunnybrook Health Sciences Centre; MOUNT SINAI HOSPITAL

Recruiting

DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk (DAPA-SWEET)

Cardiovascular Risk Factor

Canada
Shanghai Zhongshan Hospital

Active, not recruiting

Remission of Type 2 Diabetes With Dapagliflozin (READ Trial) (READ)

Type 2 Diabetes

China
Abramson Cancer Center of the University of Pennsylvania

Terminated

Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia (UPCC04407)

Acute Myeloid Leukemia

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Medical University of Vienna
Vienna Dialysis Center

Recruiting

SGLT2 Inhibition in Hemodialysis (DAPA-HD)

Diabetes Mellitus, Type 2 | Hemodialysis | Chronic Kidney Disease | Kidney Failure | Left Ventricular Hypertrophy

Austria
Damanhour University
Menoufia University

Unknown

Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial

Cardiomyopathies | Diabete Type 2 | Heart Failure With Reduced Ejection Fraction (HFrEF)
HaEmek Medical Center, Israel

Unknown

The Use of Medical-Expulsive Therapy With Alfuzocine xl 10mg x1/d for Distal Ureterolithiasis.a Randomized Prospective Study

Distal Ureterolithiasis

Israel
Miulli General Hospital

Not yet recruiting

Empagliflozin and Atrial Fibrillation Treatment (EMPA-AF)

Heart Failure | Obesity | Diabetes Mellitus | Atrial Fibrillation

Italy
National Taiwan University Hospital

Recruiting

SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning

Ventilator Lung | Heart Failure Acute

Taiwan
Beijing Anzhen Hospital

Not yet recruiting

Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation (DARE-AF)

Atrial Fibrillation

China
Rambam Health Care Campus
Boehringer Ingelheim

Unknown

Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients (ERA-HF)

Heart Failure | Diabetes Mellitus | Arrythmia
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Bioequivalence | Fixed Dose Combination Tablets | Healthy Male and Female Subjects

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions

Healthy Subjects

Canada
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions

Healthy Subjects

Canada
UCB Pharma SA

Completed

Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers

Healthy Volunteers

Netherlands
Eisai Inc.

Completed

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

Obesity

United States
AstraZeneca

Terminated

Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

Type 2 Diabetes Mellitus

Thailand, Vietnam
University Medical Center Groningen

Completed

Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure (EMPA-RESPONSE)

Heart Failure; With Decompensation | Heart Failure，Congestive | Heart Failure Acute

Netherlands
NHS Greater Glasgow and Clyde
University of Glasgow

Completed

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects (SUGAR-DM-HF)

Heart Failure | Diabetes Mellitus

United Kingdom
Sheba Medical Center

Unknown

Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

Coronary Disease With Diabetes Mellitus

Israel
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
University of Leicester
AstraZeneca; Royal Surrey County Hospital NHS Foundation Trust

Completed

The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes (SINGLED)

Type 2 Diabetes

United Kingdom
Medical University of Vienna
Attoquant Diagnostics

Completed

EMPRA (EMPagliflozin and RAs in Kidney Disease) (EMPRA)

Diabetes Mellitus, Type 2 | Diabetic Kidney Disease | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3

Austria
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
Columbia University
Bausch Health Americas, Inc.

Completed

Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

Celiac Disease

United States
Eisai Inc.

Completed

A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501

Idiopathic Thrombocytopenic Purpura

United Kingdom
SINA Health Education and Welfare Trust

Completed

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

Polycystic Ovary Syndrome | Weight Gain | HbA1c

Pakistan
Chinese PLA General Hospital

Completed

Low Dose Ruxolitinib in Combination With Methylprednisolone

Stem Cell Transplant Complications | aGVHD

China
Mount Sinai Hospital, Canada
Boehringer Ingelheim

Recruiting

Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes (EMPA post-GDM)

Gestational Diabetes

Canada
Galapagos NV

Completed

Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects

Healthy

Belgium
Saint Luke's Health System

Completed

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure (EMBRACE-HF)

Heart Failure

United States
Boehringer Ingelheim

Completed

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Healthy

Canada
Centro Universitario de Ciencias de la Salud, Mexico

Active, not recruiting

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Diabetes Mellitus Type 2 Without Complication

Mexico
Seoul National University Bundang Hospital

Recruiting

Effect of Empagliflozin on Body Composition and Ketones

Diabetes Mellitus | Fat; Intolerance, Pancreas

Korea, Republic of
Medical University of Graz
Medical University of Vienna; Johannes Kepler University of Linz; Paracelsus... and other collaborators

Completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction (EMMY)

Acute Myocardial Infarction

Austria

Search clinical trials for: Dapagliflozin 10 mg/day (oral)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations